Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2008

NicOx Signs On Archimica as Commercial Supplier of Phase III Osteoarthritis Therapeutic

  • NicOx signed an agreement with Archimica for the commercial manufacturing and supply of naproxcinod. The compound is in Phase III studies for osteoarthritis.

    The goal is to secure commercial-scale quantities to ensure the successful launch of naproxcinod. NicOx expects to file an NDA in mid-2009. Archimica will supply naproxcinod API from its Springfield, MO, facility. NicOx says that the first deliveries of significant quantities of commercial material should be made from the fourth quarter of 2009 onwards. The firm adds that it may add two additional suppliers.

    Naproxcinod is NicOx' lead investigational product and belongs to the COX-inhibiting nitric oxide-donating class of anti-inflammatory agents. The Phase III trials are designed to demonstrate that it is safe, well tolerated, effective, and has no detrimental effect on blood pressure, in contrast to existing NSAIDs.

    While NicOx plans to retain commercialization rights in the U.S. and some EU countries, the company says that it will look for partners in other regions.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »